Targeting specific tumor changes in newly diagnosed and recurrent glioblastoma
Official title: Therapeutic targeting mesenchymal transition in newly diagnosed and recurrent GBM
Funded at University of California, San Diego · NIH-10990835 · Data updated 2026-11-12
This study is looking at different types of glioblastoma, a tough brain tumor, to see how the tumor cells interact with their surroundings and why some treatments don’t work well; the goal is to find better, more targeted therapies that could help patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | September 15, 2024 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $649,226 |
| NIH project number | 1R01NS134798-01A1 |
| Project ID | NIH-10990835 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with newly diagnosed or recurrent glioblastoma.
✕Less likely to help
Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
What this research studies
This research investigates the complex nature of glioblastoma (GBM), a highly aggressive brain tumor, by focusing on its various molecular subtypes. The study aims to understand how different tumor cell interactions within the microenvironment contribute to treatment resistance. By examining the role of specific genetic mutations and their effects on tumor behavior, the research seeks to develop targeted therapies that can more effectively combat this cancer. Patients may be involved in trials that explore new treatment options based on these findings.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have gone: Previous research has shown promise in targeting specific molecular pathways in glioblastoma, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
-
University of California, San Diego
La Jolla, United States Active
Researchers
- Principal investigator: Furnari, Frank — University of California, San Diego
- Study coordinator: Furnari, Frank
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.